Sanofi India Limited

As of June 30, 2026, Sanofi India Limited carries a market capitalization of 78.45B, placing it among publicly traded companies globally. Its enterprise value stands at 74.86B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Sanofi India Limited's next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Sanofi India Limited has 23.03M shares outstanding.

As of June 30, 2026, Sanofi India Limited trades at a trailing price-to-earnings ratio of 24.72. The price-to-sales ratio is 4.52, and the price-to-book ratio stands at 9.50.

As of June 30, 2026, Sanofi India Limited trades at an EV/EBITDA multiple of 16.89 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 4.31 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 18.40 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 74.86B versus a market cap of 78.45B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Sanofi India Limited maintains a current ratio of 1.69, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.78, indicating elevated leverage, while an interest coverage ratio of 277.06 demonstrates strong ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 16.22M in revenue per employee across its workforce of 1,070.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Sanofi India Limited recorded 1.10B in income tax expense. That works out to an effective tax rate of 25.74, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 4.27B, leaving 3.17B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Sanofi India Limited's stock has declined approximately 41.01% over the past 52 weeks. The 50-day moving average sits at 3,094.28, while the 200-day moving average is 3,445.37.

Over the twelve months ended June 30, 2026, Sanofi India Limited generated 17.36B in revenue and converted that into 3.17B in net income, yielding earnings per share of 137.78. EBITDA reached 4.43B, while operating income came in at 4.07B.

As of June 30, 2026, Sanofi India Limited holds 3.74B in cash and equivalents against 147.00M in total debt, resulting in a net debt position of -3.59B. Total book value stands at 8.26B, with working capital of 3.95B providing operational flexibility.

Over the twelve months ended June 30, 2026, Sanofi India Limited posted a gross margin of 49.52, reflecting its pricing power and cost economics. The operating margin of 23.43 and net profit margin of 18.28 provide insight into operational efficiency.

Sanofi India Limited's most recent stock split took place on June 13, 2024 with a 29:50 split ratio.